17β-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative
View Patent ↗The 17β-cyano-19-nor-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO 2 R, in which R is hydrogen or C 1 -C 4 -alkyl, R 4 is hydrogen or halogen, furthermore either: R 6a , R 6b together form methylene or 1,2-ethanediyl or R 6a is hydrogen and R 6b is selected from the group comprising hydrogen, methyl and hydroxymethylene, and R 7 is selected from the group comprising hydrogen, C 1 -C 4 -alkyl, C 2 -C 3 -alkenyl and cyclopropyl, or: R 6a is hydrogen and R 6b and R 7 together form methylene or are omitted with formation of a double bond between C 6 and C 7 , R 9 , R 10 are hydrogen or are omitted with formation of a double bond between C 9 and C 10 , R 15 , R 16 are hydrogen or together form methylene, R 17 is selected from the group comprising hydrogen, C 1 -C 4 -alkyl and allyl, where at least one of the substituents R 4 , R 6a , R 6b , R 7 , R 15 , R 16 and R 17 is unequal to hydrogen or R 6b and R 7 are omitted with formation of a double bond between C 6 and C 7 , and moreover comprise their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.
1. A 17β-Cyano-19-nor-androst-4-ene derivative
that is
17β-cyano-15β,16β-methylene-19-nor-androst-4-en-3-one,
17β-cyano-17α-methyl-15β,16β-methylene-19-nor-androst-4-en-3-one,
17β-cyano-17α-ethyl-15β,16β-methylene-19-nor-androst-4-en-3-one,
17β-cyano-15β,16β-methylene-19-nor-androsta-4,6-dien-3-one,
17β-cyano-7α-methyl-15β,16β-methylene-19-nor-androsta-4-en-3-one,
17β-cyano-17α-methyl-15β,16β-methylene-19-nor-androsta-4,6-dien-3-one,
or
17β-cyano-17α-ethyl-6β,7β-methylene-15β,16β-methylene-19-nor-androst-4-en-3-one.
2. A method for oral contraception or for the treatment of pre-, peri- or postmenopausal symptoms, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 .
3. A method according to claim 2 , wherein the medicament has gestagenic and antimineralcorticoid action.
4. A pharmaceutical composition comprising at least one 17β-cyano-19-nor-androst-4-ene derivative according to claim 1 and at least one suitable pharmaceutically acceptable carrier.
5. The composition according to claim 4 , further comprising at least one oestrogen.
6. The composition according to claim 5 , wherein the oestrogen is ethinylestradiol.
7. The composition according to claim 5 , wherein the oestrogen is a natural oestrogen.
8. The composition according to claim 7 , wherein the natural oestrogen is oestradiol.
9. The composition according to claim 7 , wherein the natural oestrogen is oestradiol valerate.
10. The composition according to claim 7 , wherein the natural oestrogen is a conjugated oestrogen.